Pediatric heat-related illness emergency department volume is associated with higher temperatures and is increasing over time.

For infants and young children hospitalized with RSV infection, ziresovir reduces signs and symptoms of bronchiolitis.

The Food and Administration (FDA) has approved Otulfi (ustekinumab-aauz), a biosimilar to Stelara® (ustekinumab).

In children developing asthma, levels of the immune mediator IL-10 are lower than normal by the time these children are 6 years of age.

Supplemental allergy patch testing in patients with suspected ACD revealed allergens not detected in standard screening.

The 20-year cumulative incidence of keratinocyte carcinoma was 1.5% in those who survived childhood cancer, with most patients having several lesions.